Assay News and Research

RSS

Study identifies Etravirine and Dolutegravir as effective entry inhibitors of wild-type and predominant variants of SARS-CoV-2

Researchers identified drugs inhibiting the entry of SARS-CoV-2.

18 Apr 2022

RNA interference triggers that target SARS-CoV-2 genome

Researchers screened ribonucleic acid interference against SARS-CoV-2.

18 Apr 2022

Avasimibe inhibits SARS-CoV-2 and boosts T-cell responses

Researchers demonstrate that avasimibe-mediated inhibition of ACAT blocks the entry and fusion of SARS-CoV-2 in different cell types.

18 Apr 2022

Role of cGAS-STING in SARS-CoV-2 infection

A new study analyzes the activation of cGAS and STING can induce a type I IFN response due to SARS-CoV-2 infection.

15 Apr 2022

Durable neutralizing response against Omicron after heterologous vaccine boosting

Researchers assess the impact of homologous and heterologous primary-booster vaccine dose combinations.

15 Apr 2022

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease

Researchers investigated the longevity and intensity of the SARS-CoV-2 vaccine immune response in patients suffering from immune-mediated inflammatory diseases.

15 Apr 2022

Comparison of neutralizing antibody response following SARS-CoV-2 booster vaccination with breakthrough infection

A new study examined the serological immune responses and antibody-dependent cell-mediated phagocytosis in individuals who had either received two doses of a standard vaccine regime, a booster dose following the regime, or a breakthrough infection following vaccination.

15 Apr 2022

Researchers track COVID-fighting antibodies after vaccination

The antibodies generated by Pfizer's COVID-19 vaccine rise more slowly and decline more quickly than those generated by the Moderna vaccine, according to a new study from UVA Health.

15 Apr 2022

Study explores role of APOBEC-mediated RNA editing in SARS-CoV-2 fitness

A new study investigated whether APOBEC proteins can directly edit the RNA sequence of SARS-CoV-2 to generate C-to-U mutations.

14 Apr 2022

Reaction Biology's Novel Approach to Oncology Drug Discovery at AACR Showcase

Reaction Biology, an industry-leading provider of drug discovery services, today announced that twelve abstracts highlighting data from the Company's oncology drug discovery services platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans, Louisiana.

From Reaction Biology Corporation 13 Apr 2022

The molecular context and substrate profiles of human cell surface receptor tyrosine kinases

researchers discussed and identified the systemic functions and interactions of 52 active cell surface receptor tyrosine kinases, providing insights on RTK-RTK interactions and substrates, RTK-protein complexes, and signaling pathways.

13 Apr 2022

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

13 Apr 2022

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

In a recent study under consideration at Nature Portfolio Journal and posted to the Research Square* preprint server, researchers characterized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-specific cluster of differentiation 8 (CD8+) T cell responses.

12 Apr 2022

Antibody response following Omicron BA.2 infection is lower than BA.1

In a recent report posted to the medRxiv* preprint server, researchers determined immune responses generated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineage infections in prior virus-infected and naïve subjects.

12 Apr 2022

Development of 18 monoclonal antibodies against 9 SARS-CoV-2 proteins

A new study aimed to generate, characterize, and optimize Abs against SARS-CoV-2 proteins.

12 Apr 2022

Severe COVID-19 extremely rare among children

A new Journal of Infection study describes the findings in children who contracted SARS-CoV-2 infection in England.

12 Apr 2022

Injection-free dermally delivered subunit vaccine strongly neutralizes SARS-CoV-2 variants

Researchers in Australia have evaluated the vaccine candidature of HexaPro S protein subunit vaccine against SARS-CoV-2.

12 Apr 2022

Safety, reactogenicity, and immunogenicity of the BNT and half-m1273 mRNA COVID-19 vaccines given as a fourth dose booster

Researchers evaluated the immunogenicity of Pfizer’s BNT162b2 and Moderna’s mRNA-1273 vaccines offered as the fourth dose against SARS-CoV-2.

12 Apr 2022

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

In a recent study researchers evaluated the T cell responses elicited by full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein vaccine NVX-CoV2373.

12 Apr 2022

Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

Researchers used cryogenic electron microscopy (cryo-EM) to determine the structure of the spike (S) protein of BA.2 sub-variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) and compared them with previously determined S structures of Omicron's BA.1 sub-variant.

11 Apr 2022

Assay News and Research

Study identifies Etravirine and Dolutegravir as effective entry inhibitors of wild-type and predominant variants of SARS-CoV-2

RNA interference triggers that target SARS-CoV-2 genome

Avasimibe inhibits SARS-CoV-2 and boosts T-cell responses

Role of cGAS-STING in SARS-CoV-2 infection

Durable neutralizing response against Omicron after heterologous vaccine boosting

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease

Comparison of neutralizing antibody response following SARS-CoV-2 booster vaccination with breakthrough infection

Researchers track COVID-fighting antibodies after vaccination

Study explores role of APOBEC-mediated RNA editing in SARS-CoV-2 fitness

Reaction Biology's Novel Approach to Oncology Drug Discovery at AACR Showcase

The molecular context and substrate profiles of human cell surface receptor tyrosine kinases

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

Antibody response following Omicron BA.2 infection is lower than BA.1

Development of 18 monoclonal antibodies against 9 SARS-CoV-2 proteins

Severe COVID-19 extremely rare among children

Injection-free dermally delivered subunit vaccine strongly neutralizes SARS-CoV-2 variants

Safety, reactogenicity, and immunogenicity of the BNT and half-m1273 mRNA COVID-19 vaccines given as a fourth dose booster

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

eBook: Using iPSCs models for human disease research and drug discovery eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News